Selectivity of the multidrug resistance modulator, LY335979, for P- glycoprotein and effect on cytochrome P-450 activities

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 2, 1999, Pages 854-862

  Dantzig, A H ^a   Shepard, R L ^a   Law, K L ^a   Tabas, L ^a   Pratt, S ^a   Gillespie, J S ^a   Binkley, S N ^a   Kuhfeld, M T ^a   Starling, J J ^a   Wrighton, S A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 [4 (10,11 DIFLUOROMETHANODIBENZOSUBER 5 YL)PIPERAZIN 1 YL] 2 HYDROXYPROPOXY]QUINOLINE; CYTOCHROME P450; GLYCOPROTEIN P; LEUKOTRIENE C4; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; ZOSUQUIDAR;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HYDROXYLATION; MEMBRANE BINDING; MULTIDRUG RESISTANCE; PERMEABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ATP-BINDING CASSETTE TRANSPORTERS; CACO-2 CELLS; CELL MEMBRANE; CELL SURVIVAL; CYTOCHROME P-450 ENZYME SYSTEM; DIBENZOCYCLOHEPTENES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; ISOENZYMES; KINETICS; LEUKOTRIENE C4; MIXED FUNCTION OXYGENASES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; QUINOLINES;

EID: 0032763895     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SPC and Deeley RG (1995) Characterization of the Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 55:102-110.
2. Benet L, Kroetz D and Sheiner L (1996) Pharmacokinetics: The dynamics of drug absorption, distribution and elimination, in Goodman and Gilman's: The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW and Gilman AG eds) p 14, McGraw-Hill, New York.
3. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Wash DC) 258:1650-1654.
4. Cornwell MM, Gottesman MM and Pastan IH (1986) Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 261:7921-7928.
5. Cui Y, Konig J, Buchholz JK, Spring H, Leier I and Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929-937.
6. Czeskis BA (1997) Synthesis of multidrug resistance modulator LY335979 labeled with deuterium and tritium. J Labelled Compd Radiopharm 39:49-58.
7. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol T and Starling JJ (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56: 4171-4179.
8. Doige CA and Sharom FJ (1992) Transport properties of P-glycoprotein in plasma membrane vesicles from multidrug-resistant Chinese hamster ovary cells. Biochim Biophys Acta 1109:161-171.
9. Ford JM and Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155-199.
10. Gibaldi M (1992a) Drug Interactions: Part 1. Ann Pharmacother 26:709-713.
11. Gibaldi M (1992b) Drug interactions: Part II. Ann Pharmacother 26:829-834.
12. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC and Deeley RG (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361.
13. Hill BT (1996) Drug resistance: An overview of the current state of the art. Int J Oncol 9:197-203.
14. r 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54:5788-5792.
15. Horio M, Gottesman MM and Pastan I (1988) ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 85:3580-3584.
16. Hunter J, Jepton MA, Tsuruo T, Simmons NL and Hirst BH (1993) Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 268:14991-14997.
17. Keppler D, Cui Y, Konig J, Leier I and Nies A (1999) Export pumps for anionic conjugates encoded by MRP genes. Adv Enzyme Regul 39:in press.
18. Keppler D and Konig J (1997) Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J 11:509-516.
19. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, Baas F and Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547.
20. Krishnamachary N, Ma L, Zheng L, Safa AR and Center MS (1994) Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Oncol Res 6:119-127.
21. Kuhfeld M and Stratford R (1996) In vitro measurement of drug transport using a new diffusion chamber compatible with Millicell culture supports: Performance with CaCO-2 monolayers. Int J Pharm 133:47-57.
22. 4 and structurally related conjugates. J Biol Chem 269:27807-27810.
23. Loe DW, Almquist KC, Deeley RG and Cole SPC (1996) Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271:9675-9682.
24. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP and Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642.
25. McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL and Center MS (1989) Mechanisms of multidrug resistance in HL60 cells: Analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem Pharmacol 38:3611-3619.
26. Muller M and Sarkadi B (1997) Search for specific inhibitors of multidrug resistance in cancer. Semin Cancer Biol 8:171-182.
27. 2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J Biol Chem 263:11887-11891.
28. Norman B, Dantzig A, Hauser K, Kroin J, Law K, Palkowitz A, Shepard R, Sluka J, Starling J, Tabas L and Winter M (1997) Novel inhibitors of the multidrug resistance-associated protein (MRP). Am Assoc Cancer Research 38:226.
29. Ring B, Binkley S, VandenBranden M and Wrighton S (1996) In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6, and CYP3A. Br J Clin Pharmacol 41:181-186.
30. Schuetz EG, Beck WT and Schuetz JD (1996a) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
31. Schuetz EG, Schimkel AH, Relling MV and Schuetz JD (1996b) P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001-4005.
32. Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT and Dantzig AH (1998) Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol 66:719-727.
33. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L and Chen G (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chem Pharmacol 40:S13-S19.
34. Starling JJ, Shepard RL, Cao J, Law KL, Norman BH, Kroin JS, Ehlhardt WJ, Baughman TM, Winter MA, Bell MG, Shih C, Gruber J, Elmquist WF and Dantzig AH (1997) Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul 37:335-347.
35. Stein WD (1997) Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 77:545-590.
36. van der Hoeven T and Coon M (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomea. J Biol Chem 249:6302-6310.
37. Wacher VJ, Wu CY and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 13:129-134.
38. Wandel C, Kim RB, Kajiji S, Guengerich FP and Wood AJJ (1998) Effects of P-glycoprotein (P-gp) inhibitors on Cyp3A. Clin Pharmacol Ther 63:206.
39. Wrighton S and Ring B (1994) Inhibition of human CYP3A catalyzed 1-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 11:921-924.